Cara Therapeutics (CARA) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts CARA Hot Sheet
Join SI Premium – FREE
Cara Therapeutics (NASDAQ: CARA) reported Q1 EPS of ($0.81), $0.07 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $843 thousand versus the consensus estimate of $150 thousand.
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
- UniFirst Corp (UNF) Misses Q4 EPS by 44c
- AT&T (T) Tops Q3 EPS by 5c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
